SG11201807982UA - Substituted inhibitors of menin-mll and methods of use - Google Patents
Substituted inhibitors of menin-mll and methods of useInfo
- Publication number
- SG11201807982UA SG11201807982UA SG11201807982UA SG11201807982UA SG11201807982UA SG 11201807982U A SG11201807982U A SG 11201807982UA SG 11201807982U A SG11201807982U A SG 11201807982UA SG 11201807982U A SG11201807982U A SG 11201807982UA SG 11201807982U A SG11201807982U A SG 11201807982UA
- Authority
- SG
- Singapore
- Prior art keywords
- huron
- floor
- international
- ann arbor
- parkway
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 abstract 2
- 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 abstract 2
- 102100022102 Histone-lysine N-methyltransferase 2B Human genes 0.000 abstract 1
- 101001045848 Homo sapiens Histone-lysine N-methyltransferase 2B Proteins 0.000 abstract 1
- 101001008894 Homo sapiens Histone-lysine N-methyltransferase 2D Proteins 0.000 abstract 1
- 102100030550 Menin Human genes 0.000 abstract 1
- 101710169972 Menin Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662309372P | 2016-03-16 | 2016-03-16 | |
US201662334369P | 2016-05-10 | 2016-05-10 | |
US201662431389P | 2016-12-07 | 2016-12-07 | |
US201762446640P | 2017-01-16 | 2017-01-16 | |
PCT/US2017/022564 WO2017161028A1 (en) | 2016-03-16 | 2017-03-15 | Substituted inhibitors of menin-mll and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807982UA true SG11201807982UA (en) | 2018-10-30 |
Family
ID=59851028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807982UA SG11201807982UA (en) | 2016-03-16 | 2017-03-15 | Substituted inhibitors of menin-mll and methods of use |
Country Status (28)
Country | Link |
---|---|
US (2) | US10781218B2 (pt) |
EP (2) | EP3429591B1 (pt) |
JP (3) | JP6919977B2 (pt) |
KR (1) | KR102419531B1 (pt) |
CN (2) | CN109152784B (pt) |
AU (1) | AU2017232516B2 (pt) |
BR (1) | BR112018068703B1 (pt) |
CA (1) | CA3015847A1 (pt) |
CY (1) | CY1126066T1 (pt) |
DK (1) | DK3429591T3 (pt) |
ES (1) | ES2947636T3 (pt) |
FI (1) | FI3429591T3 (pt) |
HK (1) | HK1259232A1 (pt) |
HR (1) | HRP20230537T1 (pt) |
HU (1) | HUE061989T2 (pt) |
IL (1) | IL261606B (pt) |
LT (1) | LT3429591T (pt) |
MD (1) | MD3429591T2 (pt) |
MX (1) | MX2018011105A (pt) |
MY (1) | MY201450A (pt) |
PH (1) | PH12018501952A1 (pt) |
PL (1) | PL3429591T3 (pt) |
PT (1) | PT3429591T (pt) |
RS (1) | RS64261B1 (pt) |
SG (1) | SG11201807982UA (pt) |
SI (1) | SI3429591T1 (pt) |
TW (1) | TWI747889B (pt) |
WO (1) | WO2017161028A1 (pt) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2015011445A (es) | 2013-03-15 | 2016-04-20 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina. |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
WO2016040330A1 (en) | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
EP3302057A4 (en) | 2015-06-04 | 2018-11-21 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制menin及mll蛋白之交互作用的方法及組合物 |
GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
AU2017209935B2 (en) | 2016-01-22 | 2021-04-01 | Janssen Pharmaceutica Nv | New substituted cyanoindoline derivatives as NIK inhibitors |
WO2017125534A1 (en) | 2016-01-22 | 2017-07-27 | Janssen Pharmaceutica Nv | New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors |
IL261606B (en) | 2016-03-16 | 2022-09-01 | Kura Oncology Inc | Inhibitors of converted menin-mll and methods of use |
MA43823A (fr) | 2016-03-16 | 2018-11-28 | Kura Oncology Inc | Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation |
CA3022868A1 (en) | 2016-05-02 | 2017-11-09 | Shaomeng Wang | Piperidines as menin inhibitors |
CN109689645B (zh) | 2016-06-30 | 2022-06-03 | 杨森制药有限公司 | 作为nik抑制剂的氰基吲哚啉衍生物 |
EP3478675B1 (en) | 2016-06-30 | 2020-04-22 | Janssen Pharmaceutica NV | Heteroaromatic derivatives as nik inhibitors |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
BR112019004597A2 (pt) | 2016-09-09 | 2019-06-11 | Novartis Ag | compostos e composições como inibidores de receptores endossomais do tipo toll |
EP3512857B1 (en) | 2016-09-14 | 2021-02-24 | Janssen Pharmaceutica NV | Spiro bicyclic inhibitors of menin-mll interaction |
EP3512858B1 (en) | 2016-09-14 | 2023-11-08 | Janssen Pharmaceutica NV | Fused bicyclic inhibitors of menin-mll interaction |
WO2018089967A1 (en) | 2016-11-14 | 2018-05-17 | Virginia Commonwealth University | Inhibitors of cancer invasion, attachment, and/or metastasis |
AU2017376599B2 (en) | 2016-12-15 | 2021-10-07 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-MLL interaction |
EA201991448A1 (ru) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | Азепановые ингибиторы взаимодействия менин-mll |
US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
MX2019011412A (es) | 2017-03-31 | 2020-02-07 | Univ Michigan Regents | Piperidinas como inhibidores de menina covalentes. |
US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
CA3069138A1 (en) | 2017-07-10 | 2019-01-17 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
CA3069720A1 (en) | 2017-07-11 | 2019-01-17 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
PT3700902T (pt) | 2017-10-27 | 2023-05-30 | Boehringer Ingelheim Int | Inibidores de trpc6 |
CN111356692B (zh) * | 2017-12-19 | 2021-09-03 | 基石药业(苏州)有限公司 | Ido抑制剂 |
US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
CN111788204B (zh) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | 作为hbv复制抑制剂的取代吡咯嗪化合物 |
CR20200441A (es) | 2018-02-27 | 2021-03-15 | Incyte Corp | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b |
CN110204552B (zh) * | 2018-02-28 | 2021-08-17 | 中国科学院上海药物研究所 | 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途 |
EP3762385A4 (en) | 2018-03-09 | 2021-11-24 | Recurium IP Holdings, LLC | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDINE-3-ONE |
EP3765459A1 (en) | 2018-03-13 | 2021-01-20 | Shire Human Genetic Therapies, Inc. | Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof |
US11325921B2 (en) | 2018-03-30 | 2022-05-10 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active crosslinked cyclic secondary amine derivative |
TW202012414A (zh) | 2018-04-12 | 2020-04-01 | 美商拓臻股份有限公司 | 三環ask1抑制劑 |
CN113214220B (zh) | 2018-04-23 | 2024-04-02 | 细胞基因公司 | 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途 |
MX2020012376A (es) | 2018-05-18 | 2021-03-09 | Incyte Corp | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. |
TW202402759A (zh) | 2018-07-05 | 2024-01-16 | 美商英塞特公司 | 作為a2a/a2b抑制劑之稠合吡嗪衍生物 |
CA3113233A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
EP3856173A4 (en) * | 2018-09-26 | 2022-07-06 | Kura Oncology, Inc. | TREATMENT OF HEMATOLOGICAL MALIGNITIES WITH MENIN INHIBITORS |
EP3860989B1 (en) | 2018-10-05 | 2023-04-05 | Forma Therapeutics, Inc. | Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors |
TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
SG11202105241YA (en) | 2018-11-22 | 2021-06-29 | Qilu Regor Therapeutics Inc | Glp-1r agonists and uses thereof |
SG11202104243VA (en) | 2018-12-06 | 2021-05-28 | Daiichi Sankyo Co Ltd | Cycloalkane-1,3-diamine derivative |
TW202043205A (zh) | 2018-12-31 | 2020-12-01 | 美商拜歐米富士恩有限公司 | Menin-mll相互作用之抑制劑 |
US11603523B2 (en) | 2019-01-18 | 2023-03-14 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶 |
WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
KR20220028075A (ko) | 2019-07-03 | 2022-03-08 | 스미토모 다이니폰 파마 온콜로지, 인크. | 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도 |
KR20220064369A (ko) | 2019-08-14 | 2022-05-18 | 인사이트 코포레이션 | Cdk2 저해제로서의 이미다졸릴 피리디미딘일아민 화합물 |
JP2022549601A (ja) | 2019-09-18 | 2022-11-28 | 武田薬品工業株式会社 | ヘテロアリール血漿カリクレインインヒビター |
EP4031547A1 (en) | 2019-09-18 | 2022-07-27 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof |
BR112022006977A2 (pt) | 2019-10-11 | 2022-09-20 | Incyte Corp | Aminas bicíclicas como inibidores de cdk2 |
MX2022004874A (es) | 2019-10-25 | 2022-05-13 | Gilead Sciences Inc | Compuestos de modulacion de glp-1r. |
KR20220124176A (ko) | 2019-12-06 | 2022-09-13 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 치환된 테트라하이드로푸란 |
WO2021133809A1 (en) | 2019-12-23 | 2021-07-01 | Blueprint Medicines Corporation | Inhibitors of mutant forms of egfr |
JP2023509452A (ja) | 2020-01-03 | 2023-03-08 | バーグ エルエルシー | がんを処置するためのube2kモジュレータとしての多環式アミド |
TW202322824A (zh) | 2020-02-18 | 2023-06-16 | 美商基利科學股份有限公司 | 抗病毒化合物 |
CN111297863B (zh) * | 2020-03-30 | 2021-06-25 | 四川大学华西医院 | menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用 |
MX2022014356A (es) | 2020-05-15 | 2023-03-09 | Algen Biotechnologies Inc | Ciertas composiciones quimicas y metodos de uso de las mismas. |
EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
WO2022175752A1 (en) | 2021-02-19 | 2022-08-25 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
WO2022221514A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
JP2024514009A (ja) | 2021-04-21 | 2024-03-27 | ギリアード サイエンシーズ, インコーポレイテッド | カルボキシ-ベンズイミダゾールglp-1r調節化合物 |
CN117321049A (zh) | 2021-05-08 | 2023-12-29 | 詹森药业有限公司 | 取代的螺环衍生物 |
EP4334320A1 (en) | 2021-05-08 | 2024-03-13 | JANSSEN Pharmaceutica NV | Substituted spiro derivatives |
EP4347588A1 (en) | 2021-06-01 | 2024-04-10 | JANSSEN Pharmaceutica NV | Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives |
CN117425659A (zh) | 2021-06-03 | 2024-01-19 | 詹森药业有限公司 | 哒嗪或被螺环胺取代的1,2,4-三嗪 |
CN117412964A (zh) * | 2021-06-03 | 2024-01-16 | 首药控股(北京)股份有限公司 | 取代的杂环化合物及其应用 |
AU2022284886A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
KR20240021808A (ko) | 2021-06-17 | 2024-02-19 | 얀센 파마슈티카 엔브이 | 암과 같은 질환의 치료를 위한 (r)-n-에틸-5-플루오로-n-아이소프로필-2-((5-(2-(6-((2-메톡시에틸)(메틸)아미노)-2-메틸헥산-3-일)-2,6-다이아자스피로[3.4]옥탄-6-일)-1,2,4-트라이아진-6-일)옥시)벤즈아미드 베실레이트 염 |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
CN115515958B (zh) * | 2021-08-04 | 2023-09-29 | 成都苑东生物制药股份有限公司 | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 |
WO2023011446A1 (zh) * | 2021-08-04 | 2023-02-09 | 成都苑东生物制药股份有限公司 | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
WO2023150635A1 (en) * | 2022-02-04 | 2023-08-10 | Kura Oncology, Inc. | Treatment of hematological malignancies with menin inhibitors and p-glycoprotein inhibitors |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861A (en) | 1848-10-17 | Locking umbrella and parasol | ||
US510A (en) | 1837-12-07 | soeel | ||
US949A (en) | 1838-09-27 | Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton | ||
US5863A (en) | 1848-10-17 | Matthias p | ||
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
DE4239169A1 (de) | 1992-11-21 | 1994-05-26 | Merck Patent Gmbh | Cyclobutan - Benzol - Derivate |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
EP0821671B1 (en) | 1995-04-20 | 2000-12-27 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors |
DK0780386T3 (da) | 1995-12-20 | 2003-02-03 | Hoffmann La Roche | Matrixmetalloproteaseinhibitorer |
JP3195756B2 (ja) | 1996-07-04 | 2001-08-06 | 公子 吉水 | 潤滑補助体 |
EP0923585B1 (en) | 1996-07-18 | 2002-05-08 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
JP2000501423A (ja) | 1996-08-23 | 2000-02-08 | ファイザー インク. | アリールスルホニルアミノヒドロキサム酸誘導体 |
US5866562A (en) | 1996-10-25 | 1999-02-02 | Bayer Aktiengesellschaft | Ring-bridged bis-quinolines |
PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
ID22799A (id) | 1997-02-03 | 1999-12-09 | Pfizer Prod Inc | Turunan-turunan asam arilsulfonilamino hidroksamat |
JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | N−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
IL131123A0 (en) | 1997-02-11 | 2001-01-28 | Pfizer | Arylsulfonyl hydroxamic acid derivatives |
JPH10330377A (ja) | 1997-06-02 | 1998-12-15 | Kyowa Hakko Kogyo Co Ltd | ピペリジン誘導体 |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
US6479487B1 (en) | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
US20070208087A1 (en) | 2001-11-02 | 2007-09-06 | Sanders Virginia J | Compounds, compositions and methods for the treatment of inflammatory diseases |
WO2002088107A1 (en) | 2001-04-26 | 2002-11-07 | Eisai Co., Ltd. | Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof |
CN100343258C (zh) | 2001-04-30 | 2007-10-17 | 美国拜尔公司 | 新的4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物 |
WO2003022214A2 (en) | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
WO2004030671A2 (en) | 2002-10-02 | 2004-04-15 | Merck Patent Gmbh | Use of 4-amino-quinazolines as anti cancer agents |
AU2003255482A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
US20050222175A1 (en) | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
NZ542236A (en) | 2003-03-31 | 2008-05-30 | Predix Pharmaceuticals Holding | New piperidinylamino-thieno[2,3-d]pyrimidine compounds |
US7612078B2 (en) | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
US8362264B2 (en) | 2003-08-22 | 2013-01-29 | Dendreon Corporation | Compositions and methods for the treatment of disease associated with Trp-p8 expression |
US20050123906A1 (en) | 2003-11-06 | 2005-06-09 | Rana Tariq M. | Protein modulation |
EP1768964A1 (en) | 2004-07-06 | 2007-04-04 | Angion Biomedica Corporation | Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer |
US7553964B2 (en) | 2005-06-03 | 2009-06-30 | Abbott Laboratories | Cyclobutyl amine derivatives |
US20060281769A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators |
US20060281771A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
EP1937272A2 (en) | 2005-09-02 | 2008-07-02 | Tibotec Pharmaceuticals Ltd. | Benzodiazepines as hcv inhibitors |
EP1926798B1 (de) | 2005-09-19 | 2009-09-30 | Merck Patent GmbH | Cyclobutan- und spiro[3.3]heptanverbindungen |
FR2891829A1 (fr) | 2005-10-12 | 2007-04-13 | Sanofi Aventis Sa | Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique |
AR057579A1 (es) | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
WO2007076034A2 (en) | 2005-12-21 | 2007-07-05 | Abbott Laboratories | Anti-viral compounds |
EP2004656B1 (en) | 2006-04-07 | 2013-07-10 | Boehringer Ingelheim International GmbH | Thienopyrimidines having mnk1 /mnk2 inhibiting activity for pharmaceutical compositions |
EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
US8242078B2 (en) | 2006-10-19 | 2012-08-14 | The University Of Chicago | Therapeutics to inhibit MLL-menin interaction for treating leukemia |
EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
WO2008099019A1 (en) | 2007-02-16 | 2008-08-21 | Tibotec Pharmaceuticals Ltd. | 6-hydroxy-dibenzodiazepinones useful as hepatitis c virus inhibitors |
FR2913017A1 (fr) | 2007-02-23 | 2008-08-29 | Cerep Sa | Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire |
ATE496022T1 (de) | 2007-03-19 | 2011-02-15 | Council Scient Ind Res | Anthranilsäure-derivat als antikrebswirkstoff und verfahren zur herstellung davon |
WO2008135232A1 (en) | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
WO2008153760A1 (en) | 2007-05-25 | 2008-12-18 | Burnham Institute For Medical Research | Inhibitors of thapsigargin-induced cell death |
WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
WO2009064388A2 (en) | 2007-11-09 | 2009-05-22 | Liu Jun O | Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders |
CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
CN102105463A (zh) | 2008-05-22 | 2011-06-22 | 阿勒根公司 | 对cxcr4受体有活性的二环化合物 |
DE102008027574A1 (de) * | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
KR101354763B1 (ko) | 2008-08-25 | 2014-01-22 | 아이알엠 엘엘씨 | 헷지호그 경로 조절제 |
WO2010030757A2 (en) | 2008-09-10 | 2010-03-18 | Kalypsys Inc. | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease |
GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
TW201038572A (en) | 2009-03-25 | 2010-11-01 | Gruenenthal Gmbh | Substituted spiro-amide compounds |
CA2764622A1 (en) | 2009-06-08 | 2010-12-16 | Stefan Schunk | Substituted benzimidazoles, benzothiazoles and benzoxazoles |
WO2010147234A1 (en) | 2009-06-18 | 2010-12-23 | Banyu Pharmaceutical Co.,Ltd. | Diarylamide-spirodiamine derivative |
JP5690823B2 (ja) | 2009-07-08 | 2015-03-25 | レオ ファーマ アクティーゼルスカブ | Jak受容体およびタンパク質チロシンキナーゼ阻害薬としての複素環化合物 |
US8742100B2 (en) | 2009-07-30 | 2014-06-03 | National University Of Singapore | Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity |
CA2773131C (en) | 2009-09-04 | 2015-07-14 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
WO2011101069A2 (en) | 2010-02-22 | 2011-08-25 | Merck Patent Gmbh | Hetarylaminonaphthyridines |
WO2012022265A1 (en) | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
US9090624B2 (en) | 2011-08-04 | 2015-07-28 | Allergan, Inc. | Aromatic bycyclic derivatives as CXCR4 receptor modulators |
GB201114212D0 (en) | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
AR090037A1 (es) * | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
CN103833759A (zh) | 2012-11-23 | 2014-06-04 | 华东理工大学 | 作为blk、flt3抑制剂的蝶啶酮衍生物及其应用 |
GB201217704D0 (en) | 2012-10-03 | 2012-11-14 | Ucb Pharma Sa | Therapeutic agents |
BR112015022602A2 (pt) * | 2013-03-13 | 2017-07-18 | Univ Michigan Regents | composições compreendendo compostos de tienopirimidina e tienopiridina e métodos de uso dos mesmos |
EP2968285A4 (en) | 2013-03-13 | 2016-12-21 | Flatley Discovery Lab | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS |
US9212180B2 (en) | 2013-06-12 | 2015-12-15 | The Regents Of The University Of Michigan | Menin-MLL inhibitors and methods of use thereof |
WO2015087151A1 (en) | 2013-12-12 | 2015-06-18 | Chong Kun Dang Pharmaceutical Corp. | Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same |
EP3489232A3 (en) * | 2014-04-04 | 2019-07-31 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
US20170119769A1 (en) | 2014-06-10 | 2017-05-04 | The Trustees Of The University Of Pennsylvania | Scaffolds for inhibitors of menin-mll interactions |
WO2016040330A1 (en) * | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
CN105732636B (zh) | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
EP3302057A4 (en) | 2015-06-04 | 2018-11-21 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制menin及mll蛋白之交互作用的方法及組合物 |
MA42293A (fr) | 2015-07-02 | 2018-05-09 | Janssen Sciences Ireland Uc | Composés antibactériens |
CN108779116A (zh) | 2015-12-22 | 2018-11-09 | 生命医药公司 | 多发性内分泌瘤蛋白-mll相互作用的抑制剂 |
AR107354A1 (es) | 2016-01-13 | 2018-04-18 | Bristol Myers Squibb Co | Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock |
WO2017132398A1 (en) | 2016-01-26 | 2017-08-03 | Memorial Sloan-Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in npm1 mutant leukemia |
IL261606B (en) | 2016-03-16 | 2022-09-01 | Kura Oncology Inc | Inhibitors of converted menin-mll and methods of use |
MA43823A (fr) | 2016-03-16 | 2018-11-28 | Kura Oncology Inc | Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation |
CA3022868A1 (en) | 2016-05-02 | 2017-11-09 | Shaomeng Wang | Piperidines as menin inhibitors |
WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
MX2018015252A (es) | 2016-06-10 | 2019-04-25 | Vitae Pharmaceuticals Inc | Inhibidores de la interaccion de menina-leucemia de linaje mixto. |
WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
EP3512858B1 (en) | 2016-09-14 | 2023-11-08 | Janssen Pharmaceutica NV | Fused bicyclic inhibitors of menin-mll interaction |
CA3033239A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
EP4230627A3 (en) | 2016-09-16 | 2023-11-15 | Vitae Pharmaceuticals, LLC | Inhibitors of the menin-mll interaction |
TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
-
2017
- 2017-03-15 IL IL261606A patent/IL261606B/en unknown
- 2017-03-15 LT LTEPPCT/US2017/022564T patent/LT3429591T/lt unknown
- 2017-03-15 CN CN201780030597.6A patent/CN109152784B/zh active Active
- 2017-03-15 FI FIEP17767462.9T patent/FI3429591T3/fi active
- 2017-03-15 SI SI201731362T patent/SI3429591T1/sl unknown
- 2017-03-15 CA CA3015847A patent/CA3015847A1/en active Pending
- 2017-03-15 JP JP2018544324A patent/JP6919977B2/ja active Active
- 2017-03-15 TW TW106108622A patent/TWI747889B/zh active
- 2017-03-15 MX MX2018011105A patent/MX2018011105A/es unknown
- 2017-03-15 WO PCT/US2017/022564 patent/WO2017161028A1/en active Application Filing
- 2017-03-15 HR HRP20230537TT patent/HRP20230537T1/hr unknown
- 2017-03-15 KR KR1020187029385A patent/KR102419531B1/ko active IP Right Grant
- 2017-03-15 US US16/082,649 patent/US10781218B2/en active Active
- 2017-03-15 EP EP17767462.9A patent/EP3429591B1/en active Active
- 2017-03-15 RS RS20230441A patent/RS64261B1/sr unknown
- 2017-03-15 CN CN202210112927.9A patent/CN114539284A/zh active Pending
- 2017-03-15 DK DK17767462.9T patent/DK3429591T3/da active
- 2017-03-15 EP EP23151871.3A patent/EP4219449A3/en active Pending
- 2017-03-15 PL PL17767462.9T patent/PL3429591T3/pl unknown
- 2017-03-15 PT PT177674629T patent/PT3429591T/pt unknown
- 2017-03-15 AU AU2017232516A patent/AU2017232516B2/en active Active
- 2017-03-15 MD MDE20190122T patent/MD3429591T2/ro unknown
- 2017-03-15 SG SG11201807982UA patent/SG11201807982UA/en unknown
- 2017-03-15 MY MYPI2018001520A patent/MY201450A/en unknown
- 2017-03-15 BR BR112018068703-0A patent/BR112018068703B1/pt active IP Right Grant
- 2017-03-15 HU HUE17767462A patent/HUE061989T2/hu unknown
- 2017-03-15 ES ES17767462T patent/ES2947636T3/es active Active
-
2018
- 2018-09-11 PH PH12018501952A patent/PH12018501952A1/en unknown
-
2019
- 2019-01-24 HK HK19101290.4A patent/HK1259232A1/zh unknown
-
2020
- 2020-07-30 US US16/944,040 patent/US11673898B2/en active Active
-
2021
- 2021-07-21 JP JP2021120820A patent/JP2021183609A/ja active Pending
-
2023
- 2023-06-14 CY CY20231100277T patent/CY1126066T1/el unknown
- 2023-07-13 JP JP2023115451A patent/JP2023153820A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807982UA (en) | Substituted inhibitors of menin-mll and methods of use | |
SG11201807834WA (en) | Bridged bicyclic inhibitors of menin-mll and methods of use | |
SG11201808196UA (en) | Neoantigens and methods of their use | |
SG11201900677SA (en) | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201807538PA (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201901364VA (en) | Engineered target specific nucleases | |
SG11201803983UA (en) | Transformable tagging compositions, methods, and processes incorporating same | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201901531TA (en) | Regulation of gene expression using engineered nucleases | |
SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201804957VA (en) | Neoantigen identification, manufacture, and use | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201808528VA (en) | Modified wound dressings | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11202000145XA (en) | Methods and systems for conditionally regulating gene expression | |
SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
SG11201804936UA (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases |